Bronchiectasis: an update on current pharmacotherapy and future perspectives (Q38177329)

30 August 2017

title

Bronchiectasis: an update on current pharmacotherapy and future perspectives (English)

1 reference

30 August 2017

0 references

1 reference

Manjit K Sidhu

1

1 reference

30 August 2017

Pallavi Mandal

series ordinal

2

1 reference

30 August 2017

Adam T Hill

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

13 January 2014

1 reference

Expert Opinion on Pharmacotherapy

30 August 2017

published in

1 reference

30 August 2017

volume

15

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

505-525

1 reference

British Thoracic Society guideline for non-CF bronchiectasis

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Inhaled fluticasone in bronchiectasis: a 12 month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Inhaled steroids in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Inhaled steroids improve quality of life in patients with steady-state bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Azithromycin and the risk of cardiovascular death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.878330

10.1517/14656566.2014.878330

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference